Regeneron Pharmaceuticals, Inc. (REGN) Stock Overview
Explore Regeneron Pharmaceuticals, Inc.’s financial performance, market position, analyst ratings, and future outlook.
Regeneron Pharmaceuticals, Inc. (REGN)
Key Financials
Key Financials
Market Cap
99.2B
P/E Ratio
20.31
EPS (TTM)
$45.63
ROE
0.15%
REGN Stock Analysis & Investment Overview (NASDAQ)
Our AI-powered analysis of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) gives investors deep insight into how the stock performs on the NASDAQ exchange, its growth potential, and its market positioning. With a Meyka AI Score of B+, Regeneron Pharmaceuticals, Inc.'s NASDAQ-listed shares demonstrate moderate investment characteristics based on our machine learning models.
The current technical analysis of REGN on the NASDAQ shows an RSI of 69.98, suggesting the stock is in a a neutral condition. Our forecasting models predict a 12-month price target of $799.56 for the NASDAQ listing.
Key metrics behind Regeneron Pharmaceuticals, Inc.'s NASDAQ-traded stock include a P/E ratio of 20.31 and a market capitalization of 99.2B. Combined with our AI analysis, these give both institutional and retail investors a clear view of REGN on the NASDAQ.